Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | GUCY1B2 | O75343 | 13/20 | 0.44 |
| ▸ | GUCY1A2 | P33402 | 13/20 | 0.44 |
| ▸ | GUCY1A1 | Q02108 | 13/20 | 0.44 |
| ▸ | GUCY1B1 | Q02153 | 13/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436818 | 0.84 | GUCY1B2 (0.45) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 | |
| SCHEMBL3437386 | 0.84 | GUCY1B2 (0.52) | ADORA2AADORA1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3436826 | 0.82 | GUCY1B2 (0.47) | ADORA2AADORA1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL10269227 | 0.81 | GUCY1B2 (0.53) | ADORA2AADORA1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3437435 | 0.81 | GUCY1B2 (0.45) | ADORA2AADORA1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3437397 | 0.81 | GUCY1B2 (0.45) | ADORA2AADORA1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3437368 | 0.80 | GUCY1B2 (0.47) | ADORA2AADORA1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3437387 | 0.80 | MEN1 (0.52) | ADORA2AADORA1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3437135 | 0.80 | CYP2A6 (0.46) | ADORA2AADORA1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3437377 | 0.80 | ADORA2A (0.46) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345130-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10189809-B2 | SGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170305878-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305878-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3173407-A1 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2588465-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20140323448-A1 | sGC STIMULATORS | Ironwood Pharmaceuticals Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323448-A1 | sGC STIMULATORS | Ironwood Pharmaceuticals Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748442-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748442-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120184516-A1 | sGC Stimulators | CYCLERION THERAPEUTICS, INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184516-A1 | sGC Stimulators | CYCLERION THERAPEUTICS, INC. | 2012-07-19 | — | — | US | disclosed |
| WO-2012003405-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323448-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | ADORA2A 1776/4885ADORA1 1904/4885ADORA3 2877/4885 |
| US-20120184516-A1 | sGC Stimulators | GUCY1A1, PTGIS, GUCY1B1 | ADORA2A 1776/4885ADORA1 1904/4885ADORA3 2877/4885 |
| US-20170305878-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | ADORA2A 1776/4885ADORA1 1904/4885ADORA3 2877/4885 |
| US-10189809-B2 | SGC stimulators | GUCY1A1, PTGIS, GUCY1B1 | ADORA2A 1776/4885ADORA1 1904/4885ADORA3 2877/4885 |
| US-20190345130-A1 | SGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | ADORA2A 1776/4885ADORA1 1904/4885ADORA3 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.